Bio-Rad logo

Bio-RadBIO

NYSE

Laboratory Instruments

$378.00+3.19%

No cached AI snapshot yet for BIO.

Be the first to run a multi-agent analysis on this ticker.

Key Stats

$8.25BMarket cap
$343.1252-week high
$211.4352-week low
296,636Avg volume (30d)

7,450 employees26.99M shares outstandinglisted 1980-02-29

Next earnings ~May 5, 2026

About Bio-Rad

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Latest News

Showing market-wide stock news

Related Stocksin Laboratory Instruments

Ready to see the live AI view on BIO?

Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing BIO side-by-side with live signals.

Bio-Rad (BIO) Crash Risk? Multi-Agent AI Analysis